Novavax, Inc.
NASDAQ Global SelectTotal Valuation
Novavax, Inc. carries a market capitalization of 1.68B, placing it among publicly traded companies globally. Its enterprise value stands at 1.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.68B |
| Enterprise Value | 1.13B |
Share Statistics
Novavax, Inc. currently has 164.82M shares outstanding.
| Shares Outstanding | 164.82M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Novavax, Inc. trades at a trailing price-to-earnings ratio of 6.57. The price-to-sales ratio is 3.71, and the price-to-book ratio stands at -8.14.
| PE Ratio | 6.57 |
| PS Ratio | 3.71 |
| PB Ratio | -8.14 |
| P/TBV Ratio | -5.12 |
| P/FCF Ratio | -41.83 |
| P/OCF Ratio | -41.66 |
Enterprise Valuation
The EV/Sales ratio of 2.73 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 46.12 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.73 |
| EV / EBITDA | 23.15 |
| EV / EBIT | 46.12 |
| EV / FCF | N/A |
Financial Position
Novavax, Inc. maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -155.90, indicating conservative leverage, while an interest coverage ratio of -5.41 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.33 |
| Quick Ratio | 2.23 |
| Debt / Equity | -155.90 |
| Debt / EBITDA | -2.51 |
| Interest Coverage | -5.41 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -21.62 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -241.70 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 8.75 |
Taxes
Over the trailing twelve months, Novavax, Inc. has paid 2.42M in income taxes, reflecting an effective tax rate of 2.10.
| Income Tax | 2.42M |
| Effective Tax Rate | 2.10 |
Stock Price Statistics
Novavax, Inc.'s stock has gained approximately 31.19384% over the past 52 weeks. The 50-day moving average sits at 8.54, while the 200-day moving average is 8.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | 31.19384% |
| 50-Day Moving Average | 8.54 |
| 200-Day Moving Average | 8.54 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Novavax, Inc. generated 413.80M in revenue and converted that into -247.73M in net income, yielding earnings per share of -1.51. EBITDA reached -118.45M, while operating income came in at -136.28M.
| Revenue | 413.80M |
| Gross Profit | 325.26M |
| Operating Income | -136.28M |
| Pretax Income | -245.31M |
| Net Income | -247.73M |
| EBITDA | -118.45M |
| EBIT | -136.28M |
| Earnings Per Share (EPS) | -1.51 |
Balance Sheet
Novavax, Inc. holds 719.34M in cash and equivalents against 297.32M in total debt, resulting in a net debt position of 100.03M. Total book value stands at -190.71M, with working capital of 440.52M providing operational flexibility.
| Cash & Cash Equivalents | 719.34M |
| Total Debt | 297.32M |
| Net Debt | 100.03M |
| Equity (Book Value) | -190.71M |
| Book Value Per Share | -1.16 |
| Working Capital | 440.52M |
Cash Flow
Novavax, Inc. produced -36.90M in operating cash flow over the past twelve months.
| Operating Cash Flow | -36.90M |
| Capital Expenditures | N/A |
| Free Cash Flow | -36.90M |
| FCF Per Share | -0.23 |
Margins
Novavax, Inc. operates with a gross margin of 78.60, reflecting its pricing power and cost economics. The operating margin of -32.93 and net profit margin of -59.87 provide insight into operational efficiency.
| Gross Margin | 78.60 |
| Operating Margin | -32.93 |
| Pretax Margin | -59.28 |
| Profit Margin | -59.87 |
| EBITDA Margin | -28.63 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -4.81 |
| FCF Yield | -2.39 |
Stock Splits
Novavax, Inc.'s most recent stock split took place on May 10, 2019 with a 20:1 split ratio.
| Last Split Date | 5/10/2019 |
| Split Ratio | 20:1 |
Scores
Novavax, Inc. posts an Altman Z-Score of -6.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.29 |